Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 18, 2017

Keywords

ClinConnect Summary

This clinical trial is exploring how well a procedure called sentinel lymph node biopsy (SLNB) can find any remaining cancer cells in women who have received treatment for locally advanced breast cancer. After patients undergo neoadjuvant chemotherapy (a type of treatment given before surgery to shrink tumors), this study aims to see if SLNB is effective at detecting any residual cancer in the lymph nodes.

To be eligible for this trial, participants need to be women over 18 years old who have been diagnosed with locally advanced breast cancer and have had chemotherapy. They should not have a history of breast cancer in the same breast, and they need to show signs that their cancer has responded well to treatment. If you join the study, you'll undergo the SLNB procedure after your chemotherapy, and the results will help researchers understand how this biopsy can be used in the future. It's important to know that pregnant women and those with ongoing signs of cancer in their lymph nodes won't be able to participate.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients over 18 years of age with biopsy-proven breast cancer
• • Patients presenting with locally advanced disease in the breast (cT4) and/or in the nodes (cN2/N3) as assessed by clinical exam and imaging
• • Patients presenting to surgery clinic after receipt of NAC at outside hospital with documentation of cT4 or cN2/3 disease on initial outside physical exam and imaging studies
• • Patients receiving NAC and having a nodal complete clinical response as assessed by physical exam
• Exclusion Criteria:
• • Patients with a prior history of ipsilateral breast cancer
• • Pregnant patients
• • Patients with persistent palpable axillary nodes after NAC, as assessed by physical exam
• • Patients not consenting to ALND